With Bristol Myers in its sights, Pfizer declares itself the winner in the S1P drug race to come — but you’ll have to wait for proof
From the moment Pfizer plunked down close to $7 billion to buy Arena and jump into one of the hottest games in the industry, the pharma giant made little secret of its plan to leapfrog Bristol Myers Squibb’s rival S1P drug Zeposia (ozanimod) and claim best-in-class status from the first-in-class leader.
Today, in a swift follow to its first positive cut of the 12-week data, Pfizer scientists are declaring a clean sweep of the late-stage board with proof of durability at 52 weeks for etrasimod. But anyone waiting to line up the clinical remission rate against Zeposia is going to have to sit it out a while longer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
